Ekso Bionics Appoints Jerome Wong Interim Chief Financial Officer
May 26 2022 - 7:00AM
Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an
industry leader in exoskeleton technology for medical and
industrial use, today announced the appointment of Jerome Wong as
Interim Chief Financial Officer following the departure of current
CFO Jack Glenn. Mr. Glenn resigned effective June 17, 2022 to
pursue a new position at another public company. Mr. Glenn’s
resignation is not the result of any dispute or disagreement with
the Company including any matters relating to the Company’s
accounting practices or financial reporting.
“I am excited that Jerome has accepted the
Interim CFO role after having served as our Controller for the past
five years,” said Scott Davis, President and Chief Operating
Officer of Ekso Bionics. “Jerome brings extensive knowledge of
Ekso’s finance and accounting controls, enabling a seamless
transition as we further execute on growth opportunities.”
“Jack has been a tremendous asset to Ekso
Bionics during his nearly four-year tenure as CFO, and we are
grateful for his many contributions to the Company,” Davis added.
“We wish him well in his next opportunity and future
endeavors.”
Mr. Wong, 48, has served as the Company’s
Controller since May 2017 and brings more than 20 years of
experience in finance, accounting and strategy to this role,
focusing on high and medical technology and life sciences in public
companies. Previously, he worked for more than a decade as a
corporate controller or assistant corporate controller to companies
in the high technology and life sciences industries, including ABM
Industries, Inc. from July 2006 through September 2008, XOMA
Corporation from July 2009 through October 2014, and Pattern Energy
Group Inc. from October 2014 to December 2015. Mr. Wong is a
Canadian Chartered Professional Accountant and has a B.A. in
Finance and Accounting from The University of British Columbia.
About Ekso
Bionics®
Ekso Bionics® is a leading developer of
exoskeleton solutions that amplify human potential by supporting or
enhancing strength, endurance, and mobility across medical and
industrial applications. Founded in 2005, the Company continues to
build upon its industry-leading expertise to design some of the
most cutting-edge, innovative wearable robots available on the
market. Ekso Bionics is the only exoskeleton company to offer
technologies that range from helping those with paralysis to stand
up and walk, to enhancing human capabilities on job sites across
the globe. Ekso Bionics is headquartered in the San Francisco Bay
Area and is listed on the Nasdaq Capital Market under the symbol
“EKSO.” For more information, visit: www.eksobionics.com or follow
@EksoBionics on Twitter.
Forward-Looking Statements
Any statements contained in this press release
that do not describe historical facts may constitute
forward-looking statements. Forward-looking statements may include,
without limitation, statements regarding the transition of the
Company’s CFO. Such forward-looking statements are not meant to
predict or guarantee actual results, performance, events or
circumstances and may not be realized because they are based upon
the Company's current projections, plans, objectives, beliefs,
expectations, estimates and assumptions and are subject to a number
of risks and uncertainties and other influences, many of which the
Company has no control over. Actual results and the timing of
certain events and circumstances may differ materially from those
described by the forward-looking statements as a result of these
risks and uncertainties. Factors that may influence or contribute
to the inaccuracy of the forward-looking statements or cause actual
results to differ materially from expected or desired results may
include, without limitation, the significant length of time and
resources associated with the development of the Company's
products, the Company's failure to achieve broad market acceptance
of the Company's products, the failure of the Company’s sales and
marketing efforts or of partners to market the Company’s products
effectively, adverse results in future clinical studies of the
Company's medical device products, the failure of the Company to
obtain or maintain patent protection for the Company's technology,
the failure of the Company to obtain or maintain regulatory
approval to market the Company's medical devices, lack of product
diversification, existing or increased competition, disruptions in
the Company’s supply chain due to the ongoing COVID-19 pandemic,
and the Company's failure to implement the Company's business plans
or strategies. These and other factors are identified and described
in more detail in the Company's filings with the SEC. To learn more
about Ekso Bionics please visit the Company’s website at
www.eksobionics.com or refer to the Company’s Twitter page at
@EksoBionics. The Company does not undertake to update these
forward-looking statements.
Contact: David
Carey212-867-1768investors@eksobionics.com
Ekso Bionics (NASDAQ:EKSO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Ekso Bionics (NASDAQ:EKSO)
Historical Stock Chart
From Apr 2023 to Apr 2024